Use of L-asparaginase in acute lymphoblastic leukemia: Recommendations of the Polish adult leukemia group

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 11, 2008, Pages 664-669

  Piatkowska Jakubas, Beata ^a,i   Krawczyk Kuliś, Małgorzata ^b   Giebel, Sebastian ^b   Adamczyk Cioch, Maria ^c   Czyz, Anna ^d   Marańda, Ewa Lech ^e   Paluszewska, Monika ^f   Palłynyczko, Grazyna ^g   Piszcz, Jarosław ^h   Hołowiecki, Jerzy ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^h MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁱ JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antithrombin deficiency; Asparaginase; Native asparaginase; Pegylated

Indexed keywords

ANTITHROMBIN; ASPARAGINASE; ASPARAGINE; ASPARTATE AMMONIA LIGASE; ENOXAPARIN;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTINEOPLASTIC ACTIVITY; ANTITHROMBIN DEFICIENCY; APOPTOSIS; BLOOD CLOTTING DISORDER; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; COMA; DEMENTIA; DISEASE FREE SURVIVAL; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG HALF LIFE; ESCHERICHIA COLI; HALLUCINATION; HUMAN; HYPERGLYCEMIA; IMMUNOGENICITY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; NAUSEA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PECTOBACTERIUM CHRYSANTHEMI; POLAND; PROTEIN SYNTHESIS INHIBITION; RECOMMENDED DRUG DOSE; REVIEW; SOMNOLENCE; STUPOR; THROMBOSIS; VOMITING;

EID: 57149086305     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.518     Document Type: Review

References (26)

1. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998; 28: 97-113.
2. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med. 1953; 98: 565-582.
3. Broome JD. L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep. 1981; 65: 111-114.
4. Ortega JA, Nesbit ME Jr, Donaldson MH. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 1977; 37: 535-540.
5. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002; 99: 1986-1994.
6. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007; 109: 4164-4167.
7. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000; 18: 1525-1532.
8. Ettinger LJ, Kurtzberg J, Voute PA, et al. An open-label, multicenter study of polyethylene glycol-L- asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995; 75: 1176-1181.
9. Müller HJ, Löning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000; 110: 379-384.
10. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006; 47: 141-146.
11. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006; 91: 24-31.
12. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol. 2003; 123: 836-841.
13. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007; 109: 2744-2750.
14. Hołowiecki J, Giebel S, Krawczyk M, et al. PEG-Asparaginase as a Part of Induction Therapy for Adult Acute Lymphoblastic Leukemia. A Phase II Study by the Polish Adult Leukemia Group (PALG). 45-th Annual Meeting ofASH, 6-9.12.2003 San Diego, USA. Blood. 2003; 102: 255b.
15. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003; 101: 2529-2533.
16. Holle LM. Pegaspargase: an alternative? Ann Pharmacother. 1997; 31: 616-623.
17. Hernandez-Espinoza D, Minano A, Martinez C, et al. L-Asparaginase-induced antithrombin type I deficiency. Am J Pathol. 2006; 169: 142-153.
18. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004; 77: 331-335.
19. Mattioli Belmonte M, Gugliotta L, Delvos U, et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. Haematologica. 1991; 76: 209-214.
20. Mazzucconi MG, Gugliotta L, Leone G, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coll L-asparaginase. A GIMEMA study. Blood Coagul Fibrinotysis. 1994; 5: 23-28.
21. Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymph. 2004; 45: 1545-1549.
22. Mitchell L, Andrew M. Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003; 90: 235-244.
23. Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008; 50: 298-303.
24. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003; 97: 508-516.
25. Top PC, Tissing WJ, Kuiper JW, et al. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer. 2005; 44: 95-97.
26. Chabner BA, Loo TL. Enzyme therapy: L-asparaginase. In: Chabner BA, Longo DL (eds). Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven, Philadelphia. 1996: 485-492.